Skip to main content
OpenTrials
Completed

NCT Number: NCT02983162

Is wGRS Associated With DD Recurrence?

Rationale: Retrospectively reviewing the participants of the GODDAF database, revealed a significant association between the weighted genetic risk score and Dupuytren disease recurrence. However, a significant dose-response relation was not found. This might be caused by underestimating the recurrence rate, due to the retrospective nature of determining recurrence. Therefore, we want to do a follow-up measurement of the GODDAF participants, to see whether they suffered from recurrent disease.

Objective: We aim to determine whether the wGRS is associated with recurrent DD.

Study design: An observational study, in which the participants of the GODDAF study are followed up.

Study population: Patients affected by Dupuytren disease, aged 18-96 years, who were previously included in another study on the genetic basis of Dupuytren disease.

Intervention (if applicable): NA Main study parameters/endpoints: The main study parameter is the presence of recurrent Dupuytren disease.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Dupuytren Contracture Connective Tissue Diseases Contracture Fibroma Muscular Diseases Musculoskeletal Diseases Neoplasms Neoplasms by Histologic Type Neoplasms, Connective Tissue Neoplasms, Connective and Soft Tissue Neoplasms, Fibrous Tissue Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University Medical Center Groningen, dept Plastic Surgery

Groningen, 9700 RB, Netherlands

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • DD patient
  • participant in the GODDAF study
  • genetic data passed the quality control
  • surgical treatment of DD
  • written informed consent

Exclusion criteria

  • Decisionally incapacitated
  • Patients treated for DD with collagenase or radiotherapy

Treatment and study plan

Primary outcomes

  1. Presence of recurrent Dupuytren disease

    Time frame: 1 day

    there is only one measurement in this study

Secondary outcomes

  1. Severity of Dupuytren recurrence

    Time frame: 1 day

    there is only one measurement in this study

Sponsors and collaborators

Lead sponsor

University Medical Center Groningen

Other

Registry information

Official study title

Is the Weighted Genetic Risk Score Associated With Dupuytren Disease Recurrence?

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Dec 6, 2016
Registry last updated
Feb 10, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.